NCT06013371View on ClinicalTrials.gov

PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea

PHASE2TerminatedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

July 19, 2023

Primary Completion Date

February 18, 2025

Study Completion Date

February 18, 2025

Conditions

Seborrheic DermatitisPapulopustular Rosacea

Interventions

DRUG

PF-07038124

topical PDE4 inhibitor

DRUG

Placebo Ointment

matching placebo

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER